bluebird bio Inc. (BLUE)
| Bid | 3.8 |
| Market Cap | 37.79M |
| Revenue (ttm) | 2.67M |
| Net Income (ttm) | -15.1M |
| EPS (ttm) | -36 |
| PE Ratio (ttm) | -0.11 |
| Forward PE | -0.76 |
| Analyst | Hold |
| Ask | 3.94 |
| Volume | 135,805 |
| Avg. Volume (20D) | 337,379 |
| Open | 3.89 |
| Previous Close | 3.90 |
| Day's Range | 3.82 - 3.99 |
| 52-Week Range | 3.56 - 28.60 |
| Beta | 0.82 |
About BLUE
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinic...
Analyst Forecast
According to 7 analyst ratings, the average rating for BLUE stock is "Hold." The 12-month stock price forecast is $40, which is an increase of 930.93% from the latest price.
Stock Forecasts
1 week ago · accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUENEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
